The Science Behind TAT: Precision, Power, and Promise

A cornerstone in the battle against cancer, radiotherapy encompasses a wide variety of techniques for the elimination of malignant cells. A type of radiotherapy, Targeted Alpha Therapy (TAT), has gained notoriety in recent years. TAT offers a highly targeted method of attacking cancer cells while sparing healthy surrounding cells, a long standing concern and side effect of standard radiotherapy.

An overview of Radiotherapy

Radiotherapy, also commonly referred to as radiation therapy, is a medical treatment that uses high doses of radiation to kill cancer cells or shrink tumors. Radiotherapy is often used in combination with chemotherapy or surgical interventions in order to improve patient outcomes. Radiotherapy primarily works by damaging the DNA within cancer cells to prevent the cells from growing and dividing. The vast majority of the time, damages and mutations in DNA result in cell death. Cancer is a result of changes to DNA that do not result in cell death but result in further propagation of the damaged DNA. Cancer can be compared to an invasive weed overtaking a garden, spreading uncontrollably and choking out healthy plants. Traditional radiotherapy, like a broad-spectrum weed killer, can damage not only the weeds but also the surrounding healthy plants. In contrast, radiotherapy advancements like Targeted Alpha Therapy (TAT) act like a specialized gardener, meticulously removing the weeds without harming the flowers. TAT precisely targets and destroys cancer cells, sparing healthy tissue. This precision ensures that while the invasive cancer cells are eradicated, the surrounding healthy cells remain unaffected, effectively preventing the spread of the disease and preserving the body's overall health.

• While the majority of damages or mutations to DNA sequences result in cell death, sometimes the changed DNA can be passed on to other cells resulting in improper cell growth known as cancer.

• Radiotherapy treatments consist of high doses of precisely directed and controlled radiation in order to damage DNA of cancer cells.

How Targeted Alpha Therapy works

Targeted Alpha Therapy (TAT) is an advanced form of radiotherapy that uses alpha-emitting radionuclides to selectively target and destroy cancer cells. Here’s a step-by-step explanation of how TAT works:

1. Radionuclide Selection: A radionuclide is a radioactive atom with an unstable nucleus that releases radiation as it decays to a more stable form. This radiation can be in the form of alpha particles, beta particles, or gamma rays. In TAT, radionuclides that emit alpha particles are specifically chosen because of their high energy and short travel distance. TAT utilizes radionuclides that emit alpha particles. Alpha particles are highly energetic but travel only short distances (50-100 micrometers) in biological tissues, making them ideal for targeting cancer cells without affecting surrounding healthy cells.
   

2. Targeting Mechanism: The radionuclide is attached to a target molecule, such as an antibody, that binds specifically to receptors or antigens expressed on the surface of cancer cells. This targeting molecule ensures that the radionuclide is delivered directly to the tumor site and does not interfere with other normally functioning cells.
   

3. Administration: The TAT compound (radionuclide plus targeting molecule) is administered to the patient, typically via IV. Through IV administration, the compound circulates through the bloodstream until it binds to the cancer cells. Due to the targeting mechanism discussed above, circulation of the compound does not cause binding to other, non-target cells.
   

4. Alpha Particle Emission: Once the TAT compound binds to the cancer cells, the radionuclide emits alpha particles. These particles have a high linear energy transfer (LET), meaning they can deliver a large amount of energy over a short distance. A high LET also results in a lower number of particle emissions required to kill a cancer cell which improves the efficacy of smaller doses.
   

5. DNA Damage: The emitted alpha particles cause double-strand breaks in the DNA of the cancer cells. If only a single strand of DNA was broken, the other undamaged strand could be used to correct the damage which would decrease the efficacy of treatment. Double strand breakage is much more difficult to repair and therefore more often leads to cell death. The close proximity, (about 50-100 micrometers), of alpha particle emission minimizes damage to nearby healthy cells. For comparison, the width of a single strand of human hair ranges from around 20-200 micrometers.

6. Cell Death: The extensive DNA damage resulting from double strand breakage induces cell death. Cancer cells are killed resulting in shrinkage of the tumor.
   

7. Effectiveness: TAT is particularly effective against small clusters of cancer cells due to the short range and high energy of alpha particles. This precision allows for the treatment of cancer cells that are difficult to reach with more conventional therapies.

Advantages of TAT:

• High Specificity: The targeting mechanism ensures that the radionuclide binds specifically to cancer cells, minimizing damage to healthy tissue.
  

• Minimal Side Effects: The short range of alpha particles reduces the risk of harming surrounding healthy cells, leading to fewer side effects compared to more traditional radiotherapy.
  

• Effective on Resistant Cancer Cells: TAT can be effective on cancer cells that are resistant to other forms of treatment due to the potent and localized DNA damage caused by alpha particles.

Targeted Alpha Therapy is a highly precise and potent form of radiotherapy that leverages the properties of alpha-emitting radionuclides to selectively target and destroy cancer cells, offering a promising treatment option with minimal impact on healthy tissues.

Radioactive decay is a double-edged sword

Radioactive decay is central to radiotherapy as it provides the radiation needed to damage and kill cancer cells. Treatments like TAT harness the energy released from natural radioactive decay.

A crucial concept in radiotherapy involving radionuclides is their half-life, which is the time it takes for half of the radioactive atoms to decay and cease emitting radiation. Different radionuclides have varying half-lives, and this characteristic significantly impacts their effectiveness and safety. If a radionuclide's half-life is too short, the treatment may be less effective because insufficient radiation is delivered to the target tumors. On the other hand, if the half-life is too long, the radionuclides may continue to emit radiation even after the cancer cells are destroyed, potentially damaging healthy tissues. Achieving the right balance is essential and is further complicated by clinical logistics. When the half-life of a compound is measured in hours or minutes, even small delays in patient care can have a significant impact on the treatment's success.

Nanogenerators, amongst other technologies, are being explored to solve some of the issues caused by radioactive decay. Nanogenerators convert mechanical or thermal energy into electrical energy at the nanoscale level. Theories have arisen that nanogenerators could be utilized to create a continuous supply of radiation that would increase the efficacy of the treatment without effecting the surrounding healthy tissue.

Market trends suggest growing interest

On March 19th, 2024, pharmaceutical giant AstraZeneca announced its acquisition of Fusion Pharmaceuticals, an oncology company specializing in the development of Targeted Alpha Therapy (TAT) technologies. AstraZeneca agreed to buy shares at a 97% premium, valuing them at $21.00 per share, significantly higher than the previous closing market price of $10.64 per share. The agreement also includes a $3 non-transferable contingent value right, which becomes effective upon achieving a specified regulatory milestone. This brings the maximum potential value of the acquisition to $2.4 billion. AstraZeneca, aiming for $80 billion in sales by 2030, is expected to continue investing heavily in its expanding oncology drug portfolio, including radiopharmaceuticals such as Targeted Alpha Therapy (TAT).

At BioBeacon, we value community insight and would love to hear your thoughts! Join the discussion by leaving a comment below. Have questions or insights to share? Feel free to reach out and get in touch with us. Your engagement is invaluable, and together we can explore the future of biotechnology and medicine. Don't forget to share this post with your network and keep the conversation going!